Critical Analysis: aTyr Pharma (NASDAQ:ATYR) vs. CRISPR Therapeutics (NASDAQ:CRSP)

aTyr Pharma (NASDAQ:ATYR) and CRISPR Therapeutics (NASDAQ:CRSP) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, risk, valuation, profitability, dividends and earnings.

Risk & Volatility

aTyr Pharma has a beta of 0.91, suggesting that its stock price is 9% less volatile than the S&P 500. Comparatively, CRISPR Therapeutics has a beta of 1.76, suggesting that its stock price is 76% more volatile than the S&P 500.

Profitability

This table compares aTyr Pharma and CRISPR Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
aTyr Pharma	N/A	-95.89%	-69.67%
CRISPR Therapeutics	-3,368.72%	-24.39%	-18.25%

Institutional & Insider Ownership

61.7% of aTyr Pharma shares are owned by institutional investors. Comparatively, 69.2% of CRISPR Therapeutics shares are owned by institutional investors. 5.0% of aTyr Pharma shares are owned by company insiders. Comparatively, 5.2% of CRISPR Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Analyst Recommendations

This is a summary of recent recommendations and price targets for aTyr Pharma and CRISPR Therapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
aTyr Pharma	1	0	1	1	2.67
CRISPR Therapeutics	1	7	9	2	2.63

CRISPR Therapeutics has a consensus price target of $65.75, indicating a potential upside of 27.87%. Given CRISPR Therapeutics’ higher possible upside, analysts clearly believe CRISPR Therapeutics is more favorable than aTyr Pharma.

Earnings and Valuation

This table compares aTyr Pharma and CRISPR Therapeutics”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
aTyr Pharma	$190,000.00	63.70	-$74.12 million	($24.80)	-0.20
CRISPR Therapeutics	$3.51 million	1,416.47	-$581.60 million	($4.76)	-10.80

aTyr Pharma has higher earnings, but lower revenue than CRISPR Therapeutics. CRISPR Therapeutics is trading at a lower price-to-earnings ratio than aTyr Pharma, indicating that it is currently the more affordable of the two stocks.

Summary

CRISPR Therapeutics beats aTyr Pharma on 11 of the 15 factors compared between the two stocks.

About aTyr Pharma

aTyr Pharma, Inc. engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.